Adlai Nortye Past Earnings Performance
Past criteria checks 0/6
Adlai Nortye's earnings have been declining at an average annual rate of -12.7%, while the Biotechs industry saw earnings growing at 11.8% annually.
Key information
-12.7%
Earnings growth rate
6.4%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -101.3% |
| Net Margin | -1,081.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Adlai Nortye makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 5 | -54 | 15 | 57 |
| 31 Mar 24 | 5 | -104 | 15 | 58 |
| 31 Dec 23 | 5 | -105 | 15 | 58 |
| 30 Sep 23 | 3 | -114 | 13 | 59 |
| 30 Jun 23 | 0 | -123 | 11 | 60 |
| 31 Mar 23 | 0 | -63 | 13 | 59 |
| 31 Dec 22 | 0 | -59 | 13 | 54 |
| 31 Dec 21 | 46 | -57 | 12 | 42 |
Quality Earnings: N2U0 is currently unprofitable.
Growing Profit Margin: N2U0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: N2U0 is unprofitable, and losses have increased over the past 5 years at a rate of 12.7% per year.
Accelerating Growth: Unable to compare N2U0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: N2U0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-0.08%).
Return on Equity
High ROE: N2U0 has a negative Return on Equity (-101.3%), as it is currently unprofitable.